Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
Auteurs : Thouvenin J, Martinez Chanza N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG Jaar : 2021 Journal : Cancers (Basel)
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Auteurs : Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK Jaar : 2021 Journal : JAMA Oncol
<sup>68</sup>Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
Auteurs : Shagera QA, Artigas C, Karfis I, Critchi G, Martinez Chanza N, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P Jaar : 2021 Journal : J Nucl Med
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Auteurs : Albisinni S, Martinez Chanza N, Aoun F, Diamand R, Mjaess G, Azzo JM, Esperto F, Bellmunt J, Roumeguère T, DE Nunzio C Jaar : 2021 Journal : Minerva Urol Nephrol
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ Jaar : 2021 Journal : Prostate Cancer Prostatic Dis